ASH 2022 | Safety & efficacy of isatuximab, pomalidomide and dexamethasone in frail patients with R/R myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines findings from a UK-wide cohort which evaluated the efficacy of isatuximab with pomalidomide and dexamethasone as a fourth-line treatment for frail patients with relapsed/refractory (R/R) multiple myeloma. Overall, whilst the study found clinical benefits of this novel combinational therapy in frail patients, there were also higher rates of treatment discontinuation, a higher toxicity burden and a lower progression-free survival (PFS) in frail patients when compared to fitter patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Bristol Myers Squibb, Janssen, Amgen, GlaxoSmithKline: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Research Funding, Speakers Bureau; Sanofi, Adaptive biotech, Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
